Patient Information Sheet for Trans women and Non-binary People v2.0

HPV Methylation Self-testing Pilot in Transgender Individuals



We invite you to take part in a research study

- Before you make your decision, it is important for you to understand why we are asking you to take part and what it will involve.
- Please take time to read the following information carefully. Discuss it with your friends, relatives, or another clinician if you wish.
- You are free to decide whether to take part. If you choose not to, this will not affect any other aspects of your care. You can withdraw your consent to take part at any time.
- Ask us if there is anything that is not clear or if you would like more information.

Why is this study being done?

- The human papillomavirus (HPV) is a virus that is transmitted through skin-to-skin contact, most often through sexual contact. Most HPV infections are mild and clear within two years. However, on rare occasions, some types of HPV can cause a type of cancer that can affect the cervix, vagina, labia, anus, or throat.
- Cervical screening is currently offered to those born with a cervix, however not much is known about the effects of high-risk types of HPV on trans women and non-binary people who were assigned male at birth.
- This study will investigate how common HPV is among in trans people assigned male at birth who have undergone vaginoplasty. We will look for HPV in the anus, throat, vagina and urine and how widely accepted screening those parts of the body might be.
- It will also investigate a new way of testing for HPV in the laboratory by looking for changes in DNA of the virus (called methylation).

What are the possible benefits of taking part?

- The information we get from this study could help improve the HPV screening for transgender and non-binary people in the future.
- The findings of this study may contribute to helping prevent cancers.
- You will receive a £20 gift card by email once you complete the survey component of the study.

What are the disadvantages of taking part?

- We cannot promise the study will help you directly and you will not receive any extra treatment by taking part.
- It might mean your appointment takes a little longer while we discuss the study and explain self-sampling.
- You will need to take extra samples yourself at home and return them by post.
- There is a chance you could experience physical discomfort from swabbing and a small chance of light bleeding afterwards. This should stop on its own but you should tell the clinic or your own doctor if it doesn't.


- Very rarely, you could develop an infection after self-swabbing and you should tell the clinic or your own doctor if this happens.
- It is possible you could experience dysphoria or emotional distress from swabbing or from completing our medical questionnaire or survey. This may be more likely if you have had a previous traumatic experience. If this happens, we will signpost you to further sources of support.

What happens if I don't take part?

Taking part in this study is entirely optional. If you decide not to take part, it will not change the care you receive.

What will happen during the study?

- A clinician will first check that you are eligible to take part in the study and provide you with all the information needed to get your informed consent.
- If you join the study, you will be asked to fill out some forms about your demographics and medical history.
- You will be asked to collect 7 self-samples in total.
- You will be given instructions on how to take the initial 4 self-samples required for this study whilst in clinic.
- 3 more self-samples will need to be completed at home, with the help of instructions and diagrams, and then mailed back to us in the box provided.
- You will be sent a survey by email about y our experience, as well as questions on your health knowledge and sexual practices. This will take about 20 minutes.



What happens after the study?

• HPV can be cleared from the body by the immune system, so if any of your samples are HPV positive, they may not be in a year. HPV tends to take years to cause harm. For this reason, we will not routinely send you the results of your study samples.

- Please visit your GP if you experience any concerning symptoms such as bleeding or discomfort in the areas sampled. If your GP has concerns, they can have call with a study clinician to discuss further.
- We hope that the overall results of the study will be available in the next two years.

What will happen to my samples?

Your samples will be sent to the United States where they will be stored until all participants samples have been collected. They will then all be tested for HPV by using an established test and the experimental methylation test. We may also look at some of the samples under the microscope. We will keep your samples for testing within this study for up to 5 years.

We will ask your permission to keep additional samples for use in future research into HPV by the same study team. This includes looking at DNA from the virus but also your own cells in the sample. Nobody outside the study team will be able to use your samples.

If you give permission for us to do this, after 5 years, we will remove DNA from the cells for storage and dispose of remaining sample. If you do not give permission, all remaining samples belonging to you will be destroyed at the end of 5 years.

How will we use information about you?

We will need to use information from you for this research project.

This information will include your name, date of birth, telephone number and email address. People will use this information to do the research or to check your records to make sure that the research is being done properly.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead. We will keep all information about you safe and secure.

Some of your information will be sent to the United States of America They must follow our rules about keeping your information safe.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

What are your choices about how your information is used?

You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.

We need to manage your records in specific ways for the research to be reliable. This means that we won't be able to let you see or change the data we hold about you.

If you agree to take part in this study, you will have the option to take part in future research using your data saved from this study.

Where can you find out more about how your information is used?

You can find out more about how we use your information:

- at <u>www.hra.nhs.uk/information-about-patients/</u>
- by asking one of the research team, or
- by sending an email to ____

The research sponsor's Data Protection Officer can be contacted via email to:

data-protection@qmul.ac.uk

What if I change my mind?

If you change your mind, you should inform your recruiting site as soon as possible either by speaking to the research team at the appointment or afterwards using the email_______.

You can tell us which of your samples or data you allow to continue to be included in the study. Please note if the study results have been analysed, it will no longer be possible for your data to be removed. Any of your remaining samples can be destroyed. This will not affect your care in any way.

Will my GP know I have taken part?

Your GP will not know you have participated in this study. Your care team can tell you more about whether other tests at your visit will be available to your GP.

What if something goes wrong?

How have patients and the public been involved in this study?

This study was codesigned and coproduced with members of the transgender and non-binary community on the research team. We have formed a Community Advisory Board who have reviewed the overall study and its documents, including this information sheet. This Board will also guide us on the best ways to tell the community about the results of the study and review any publications of the study results.

Who is carrying out the study?

The sponsor for the study is Queen Mary, University of London. This a collaborative project between:

- Queen Mary University of London UK
- National Cancer Institute (NCI) USA
- The study is funded by the NCI.

This study has been approved by the local Research Ethics Committee. *IRAS number: 319364*

How to contact us

If you want to learn more, or have any questions about this study, you can contact the study team at your clinic: